Kymera and Sanofi Advance IRAK4 Program With Selection of KT-485 for Clinical Development
US-based Kymera Therapeutics Inc. (NASDAQ: KYMR) announced updates to its IRAK4-targeted program collaboration with Sanofi....
Kymera Therapeutics
Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD
US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and...
Kymera Therapeutics’ Stock Soars on Sanofi’s Plans to Expand KT-474 Clinical Trials
Kymera Therapeutics Inc. (NASDAQ: KYMR), a biopharmaceutical company based in the U.S., has announced that...